BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in March: TD Cowen 45th Annual Health Care Conference Presentation DetailsFireside Chat Date: Tuesday, March 4, 2025Fireside Chat Time: 11:50 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Boston, MA Leerink Partners Glob ...

BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. Presentation Details: OTX-TKI From Phase 1 to Phase 3: SOL-1 and SOL-R Trials for Neovascular AMDSession: V: Imaging and Emerging Therapies for Exudative AMDPresentation Time: 2:30 PM ETPresenter: Carl J. D ...

311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational trial, SOL-1, completed randomization in December 2024 with topline data anticipated in Q4 2025 Company plans to seek FDA feedback in H1 2025 on clinical trial design for AXPAXLI in NPDR BEDFORD, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmace ...

Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for re ...

I have been covering Ocular Therapeutix (NASDAQ: OCUL ) for a while now, and I have not been bullish. However, the stock has not done poorly, and their programs have progressed well. Since my last coverage inAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring h ...

BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December. Piper Sandler 36th Annual Healthcare ConferenceFireside Chat Date: Tuesday, December 3rd, 2024 Firesi ...

Financial Data and Key Metrics Changes - The company reported cash and cash equivalents of approximately $427 million at the end of Q3 2024, providing a runway into 2028 and fully funding the SOL-1 and SOL-R trials to top-line results [27]. Business Line Data and Key Metrics Changes - The company is focused on the clinical development of AXPAXLI for wet age-related macular degeneration (AMD), with significant progress in enrollment for the SOL-1 and SOL-R trials [5][10]. - SOL-1 has reached a key enrollment milestone, and the company expects to complete randomization by year-end 2024, with top-line data anticipated in Q4 2025 [29]. Market Data and Key Metrics Changes - The market for wet AMD is large and underserved, with approximately 1.65 million people affected in the U.S., and up to 40% of patients discontinuing treatment within the first year [5]. Company Strategy and Development Direction - The company aims to become a leader in the treatment of retinal diseases, with a clear mission to improve vision in the real world [28]. - AXPAXLI is positioned to potentially offer a differentiated product label, focusing on treatment durability and repeatability, which may provide both regulatory and commercial advantages [38]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential success of AXPAXLI based on historical clinical data and the strong demand for participation in clinical studies, indicating a positive outlook for commercial interest [20][24]. - The company is preparing for a significant year in 2025, anticipating impactful milestones with clinical data expected [30]. Other Important Information - The company has taken steps to build its commercial infrastructure to support the manufacture and distribution of AXPAXLI to retina specialists, with plans to expand these efforts in 2025 [26]. Q&A Session Summary Question: How many of the sites for SOL-1 and SOL-R are currently overlapping? - Management confirmed that there are overlapping sites by design, allowing for a seamless transition between SOL-1 and SOL-R, and additional sites are being activated for SOL-R [33]. Question: Can you define what a differentiated product label for AXPAXLI would look like? - Management indicated that the label may include flexibility in treatment frequency and superiority over existing treatments, addressing key clinical questions [36][38]. Question: Will you provide regular updates on SOL-R enrollment progress? - Management stated that updates will be provided as appropriate, emphasizing the seamless transition from SOL-1 to SOL-R and the encouraging recruitment pace for SOL-R [40]. Question: What is the progress of discussions with EMA? - Management confirmed ongoing discussions with regulatory agencies outside the U.S. but did not provide specific details at this time [44]. Question: Can you elaborate on the commercial efforts for AXPAXLI? - Management expressed confidence in achieving premium pricing for AXPAXLI and highlighted the strength of the commercial team that has been successful with DEXTENZA [49]. Question: What are the expectations for the next trial in diabetic retinopathy? - Management indicated a commitment to pursuing diabetic retinopathy and diabetic macular edema, with a focus on preventing vision-threatening complications [56][59]. Question: Will data from SOL-1 and SOL-R need to be submitted simultaneously for regulatory approval? - Management clarified that both studies are required for approval, and they are in close collaboration with the FDA regarding the regulatory path [62].

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.04%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.22 per share when it actually produced a loss of $0.24, delivering a surprise of -9.09%.Over the last four quarters, the co ...

BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV. Jefferies London Healthcare Conference 2024Fireside Chat Date: Wednesday, Nov ...